4/9 PR The Company is now positioning itself to f
Post# of 72444
The Company is now positioning itself to further advance Brilacidin, most immediately, in its planned Phase 3 Oral Mucositis program, and in mid-stage testing for Inflammatory Bowel Disease.
Did Dr. B think a 1 and done HUGE SUCCESS meeting with EMA like some on this board did?

